Pirfenidone: An update on clinical trial data and insights from everyday practice

European Respiratory Review

Volumn 23, Issue 131, 2014, Pages 111-117

  Kreuter, Michael ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Heidelberg Translational Lung Research Center (TLRC)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIRFENIDONE; PLACEBO;

ANTIINFLAMMATORY ACTIVITY; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GASTROINTESTINAL DISEASE; HUMAN; LONG TERM CARE; OBSTRUCTIVE AIRWAY DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE;

CLINICAL TRIALS, PHASE III AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY SYSTEM AGENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84895425995     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008513     Document Type: Review

References (17)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-440.
3. Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504.
4. Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 2013; 14: Suppl. 1, S5
5. Cottin V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur Respir Rev 2012; 21: 161-167.
6. Antoniou KM, Margaritopoulos GA, Siafakas NM. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 2013; 22: 281-291.
7. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-1769.
8. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-1047.
9. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-829.
10. Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011; 20: 85-97.
11. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010; 9: CD003134.
12. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011; 183: 1231-1237.
13. du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-1389.
14. Costabel U, Albera C, Cohen A, et al. The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): interim data from the RECAP extension study. Eur Respir J 2011; 38: Suppl. 55, 3s
15. Wijsenbeek MS, Van Beek FT, Geel AL. Pirfenidone in daily clinical use in patients with idiopathic pulmonary fibrosis in the Netherlands. Am J Respir Crit Care Med 2013; 187: A4340.
16. Erasmus Medical Center. The effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis (Cough-IPF). NCT02009293. http://clinicaltrials.gov/ct2/show/NCT02009293 Date last updated: December 8, 2013. Date last accessed: December 8, 2013.
17. Oltmanns U, Kahn N, Wenz H, et al. Pirfenidone in idiopathic pulmonary fibrosis-real life experience from a German tertiary referral centre for interstitial lung diseases. Eur Respir J 2013; 42: Suppl. 57, 476s